Home/Medicines/Toceranib Phosphate

Toceranib Phosphate

Prescription

Tyrosine kinase inhibitor — antineoplastic

Last reviewed 19 Apr 2026 · PetCare.AI Editorial Team

Species

Dog

Brands

1 available

Interactions

1 documented

Formulations

Mechanism of action

Inhibits multiple receptor tyrosine kinases including KIT, VEGFR, and PDGFR, blocking tumor cell proliferation and angiogenesis

At a glance

Class

Tyrosine kinase inhibitor — antineoplastic

Schedule

Prescription

Storage

Store below 30°C; handle with gloves (cytotoxic)

Dosing

🐕

Dog

Mast cell tumors (Patnaik grade II/III, recurrent/non-resectable) / Various solid tumors

Dose

2.5–3.25 mg/kg

Route

Frequency

Every other day (MWF)

Max dose

150 mg

Duration: Long-term or until progression; dose reductions common

Educational reference only

This information is provided for educational purposes and is not a substitute for professional veterinary advice, diagnosis, or treatment. Always consult a qualified veterinarian before administering any medication to your pet. Find a vet near you →

Formulations

💊

Tablet — 3

Strength

10mg

Strength

15mg

Strength

50mg

Storage

Store below 30°C; handle with gloves (cytotoxic)

Safety

Absolute contraindications — do not use

Cats (not approved, limited safety data)

Use with caution

GI bleeding / Active GI ulceration
Concurrent NSAIDs
Increased GI toxicity

Adverse effects

Common

Diarrhoea

Inappetence

Lethargy

Weight loss

Lameness

Serious

GI hemorrhage/perforation

Neutropenia

Hepatotoxicity

Proteinuria

Hypertension

Monitoring parameters

CBC every 2 weeks initiallyUrinalysis (proteinuria)Blood pressureHepatic enzymesBody weight

Educational reference only

Interactions

Major — 1

Meloxicam

major

Toceranib has anti-VEGF activity causing GI mucosal damage; NSAIDs compound GI ulceration risk

Management: Avoid concurrent NSAIDs. If anti-inflammatory needed, use low-dose prednisolone with GI protectants.

Educational reference only

Brands

International

Palladia

Zoetis

FAQs

Frequently asked questions

›What is Toceranib Phosphate?

Toceranib Phosphate is a tyrosine kinase inhibitor — antineoplastic used in pets. Inhibits multiple receptor tyrosine kinases including KIT, VEGFR, and PDGFR, blocking tumor cell proliferation and angiogenesis

›What is Toceranib Phosphate used for in pets?

Toceranib Phosphate is used in veterinary medicine for: Mast cell tumors (Patnaik grade II/III, recurrent/non-resectable) / Various solid tumors.

›What is the Toceranib Phosphate dose for dogs?

For dogs, Toceranib Phosphate is typically dosed as follows — Mast cell tumors (Patnaik grade II/III, recurrent/non-resectable) / Various solid tumors: 2.5–3.25 mg/kg PO Every other day (MWF). Always consult your veterinarian for a dose tailored to your pet's weight, age, and condition.

›What are the side effects of Toceranib Phosphate?

Common: Diarrhoea, Inappetence, Lethargy, Weight loss, Lameness. Serious (call your vet immediately): GI hemorrhage/perforation, Neutropenia, Hepatotoxicity, Proteinuria, Hypertension.

›Does Toceranib Phosphate need a prescription?

Yes. Toceranib Phosphate is a prescription medication and should only be administered under veterinary supervision.

›When should Toceranib Phosphate not be used?

Do not use Toceranib Phosphate if: Cats (not approved, limited safety data).

Educational reference only

References

The PetCare.AI drug reference is built from 13 authoritative sources cited across 580 drug monographs.

Textbooks & handbooks — 5

Plumb's Veterinary Drug Handbook
Withrow & MacEwen's Small Animal Clinical Oncology
Merck Veterinary Manual
NRC Nutrient Requirements of Dogs and Cats
Veterinary Pharmacology and Therapeutics (Riviere & Papich)

Clinical guidelines & consensus — 4

ASPCA Animal Poison Control Center Guidelines
AAHA Diabetes Management Guidelines
ASPCA Poison Control Guidelines
RECOVER CPR Guidelines

Journals & peer-reviewed studies — 2

EPIC Study (J Vet Intern Med 2016)
JVIM FAT CAT Study

Regulatory & approvals — 1

CDSCO Veterinary Drug Approval Registry (1969–2026)

Databases — 1

Washington State University VCPL MDR1 Database

Related medicines

Other medicines in the same class (Tyrosine kinase inhibitor).

Masitinib

Selectively inhibits c-Kit (CD117) tyrosine kinase, blocking stem cell factor (SCF)-dependent signaling involved in mast cell tumor growth, survival, and differentiation. Also inhibits PDGFR and FAK.

dogcat